In Yantai, China on September 17, 2025, RemeGen shared updates regarding the 48-week open-label extension (OLE) data from the China Phase III clinical trial of telitacicept (known as RC18 and 泰爱®). This innovative drug, a BLyS/APRIL dual-target fusion protein, was developed independently. The company behind this drug is listed as 688331.SH on the Shanghai Stock Exchange and 09995.HK on the Hong Kong Stock Exchange.